QUALCOMM (NASDAQ:QCOM) Chairman Paul E. Jacobs unloaded 70,000 shares of QUALCOMM stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $75.23, for a total value of $5,266,100.00.QUALCOMM, Inc. (NASDAQ:QCOM) stock performance was 3.05% in last session and finished the day at $77.02. Traded volume was 13,822,757 million…
The iShares Biotechnology Indexhas fallen 2.46% in the last month of trading, and biotech stalwarts Celgene (NASDAQ:CELG) and Gilead Sciences (NASDAQ:GILD ) are both down over 8%. What’s most surprising is that Celgene and Gilead are expected to have strong years in terms of earnings and the development of their respective clinical pipelines. Gilead Sciences,…
Geron Corporation (NASDAQ:GERN) got bad news about its key imetelstat drug, as the FDA issued a clinical hold on the treatment for multiple myeloma and essential thrombocythemia. Geron Corporation (NASDAQ:GERN) stock performance was -61.59% in last session and finished the day at $1.69. Traded volume was 46,444,384 million shares in the last session and the…
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) reported financial results for the fourth quarter and full year ended December 31, 2013 and provided an update on corporate developments. Net loss for the fourth quarter ended December 31, 2013 was $74.2 million, or $0.40 per share, compared to a net loss of $60.5 million, or $0.36 per share, for…
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)’s shares declined 1.14% to $8.65. The company on Feb. 25 reported financial results for the fourth quarter and full year ended December 31, 2013 and provided an update on corporate developments. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock performance was -2.87% in last session and finished the day at $8.13. Traded volume was…
Officials with Zogenix Inc. (NASDAQ:ZGNX), the San Diego-based maker of Zohydro, did not return a message seeking comment about the drug. The company is marketing the drug as the first extended-release hydrocodone pain reliever without acetaminophen, which can cause liver failure if taken in excess. Zogenix, Inc. (NASDAQ:ZGNX) stock performance was -14.18% in last session…
